Selected Publications

2025

1. Meder L, Orschel CI, ... Noh KW, ... et al. ERBB2 signaling drives immune cell evasion and resistance against immunotherapy in small cell lung cancer. Nat Commun, 2025. 

2. Noh KW, Tolkach Y, Helbig D, ..., et al. Multimodal approach predicts relapse upon cessation of immune checkpoint inhibitors in advanced melanoma. Clin Can Res, 2025. doi: 10.1158/1078-0432.CCR-25-0889.

3. Schreurs LD, Vom Stein AF, …, Noh KW, Buettner R, …, et al. The immune landscape in brain metastasis. Neuro-Oncology, 2025. doi: 10.1093/neuonc/noae219.

2024

1. Baek S, Mairinger FD, Borchert S, …, Noh KW. Comparative analysis of digital transcriptomics between pre- and post-treatment samples of patients with locally advanced cervical cancer: a preliminary study. CIMB, 2024. doi: 10.3390/cimb46110716.

2. Baek S, Noh KW, …, et al. Neoadjuvant chemotherapy with the angiogenesis inhibitor bevacizumab for locally advanced cervical cancer. In vivo, 2024. doi: 10.21873/invivo.13791.

2023

1. C Alidousty, …, Noh KW, …, AM Schultheis. Frequency and functional characterization of fusion genes in squamous cell carcinoma of the lung. Gene, 2024. https://doi.org/10.1016/j.gene.2023.148018.

2. Gewalt T, Noh KW, Meder L. The role of LIN28B in tumor progression and metastasis in solid tumor entities. Oncol Res, 2023. doi: 10.32604/or.2023.028105.

2014 ~ 2022

1. Gupta V*, Noh KW*, …, Welter S, et al. A unique case of thoracic endometriosis syndrome and pulmonary Langerhans’ cell histiocytosis: Six recurrent pneumothoraces. Respir Med Case Rep, 2022. https://doi.org/10.1016/j.rmcr.2022.1016 03. *Co-First.

2. Klein S, …, Noh KW, …, Wuerdemann N, et al. Deep learning predicts HPV-association in oropharyngeal squamous cell carcinomas and identifies patients with a favorable prognosis using regular H&E stains. Clin Can Res, 2021. https://doi.org/10.1158/1078-0432.CCR-20-3596.

3. Klein S, …, Noh KW, …, Helbig D. Tumor infiltrating lymphocyte clusters are associated with response to immune checkpoint inhibition in BRAF V600E/K mutated malignant melanomas. Sci Rep, 2021. https://doi.org/10.1038/s41598-021-81330-4.

4. Jung K, …, Noh KW, …, Choi YL. TM4SF4 and LRRK2 are potential therapeutic targets in lung and breast cancers through outlier analysis. Cancer Res Treat, 2021. https://doi.org/10.4143/crt.2020.434.

5. Noh KW, Buettner R, Klein S. Shifting gears in precision oncology - Challenges and opportunities of integrative data analysis. Biomolecules, 2021. 11(9), 1310; https://doi.org/10.3390/biom11091310.

6. Klein S, Quaas A, Noh KW, …, Helbig D. Integrative analysis of pleomorphic dermal sarcomas reveals fibroblastic differentiation and susceptibility to immunotherapy. Clin Can Res, 2020. https://doi.org/10.1158/1078-0432.CCR-20-1899.

7. Klein S, …, Noh KW, …, Büttner R. Deep learning for sensitive detection of Helicobacter Pylori in gastric biopsies. BMC Gastroenterol, 2020. https://doi.org/10.1186/s12876-020-01494-7.

8. Yun JW, …, Noh KW, …, Park PJ. Dysregulation of cancer genes by recurrent intergenic fusions. Genome Biol, 2020. https://doi.org/10.1186/s13059-020-02076-2.

9. Park HK, …, Noh KW, …, Choi YL. Molecular changes in solitary fibrous tumor progression. J Mol Med, 2019. https://doi.org/10.1007/s00109-019-01815-8.

10. Klein S, Persa OD, Mauch C, …, Noh KW, …, Helbig D. First report on two cases of pleomorphic dermal sarcoma successfully treated with immune checkpoint inhibitors. Oncoimmunology, 2019. https://doi.org/10.1080/2162402X.2019.1665977.

11. Noh KW, Sohn IS, …, Choi YL. Integrin B3 inhibition enhances the antitumor activity of ALK inhibitor in ALK-rearranged NSCLC. Clin Can Res, 2018. https://doi.org/10.1158/1078-0432.CCR-17-3492.

12. Noh KW, Lee MS, …, Choi YL. Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer. J Pathol, 2017. https://doi.org/10.1002/path.4950.

13. Lee MS, Kim RN, …, Noh KW, …, Choi YL. Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma. Oncotarget, 2016. https://doi.org/10.18632/oncotarget.9137.

14. Kim YJ, Hong S, …, Noh KW, …, Choi YL. LYN expression predicts the response to dasatinib in a subpopulation of lung adenocarcinoma patients. Oncotarget, 2016. https://doi.org/10.18632/oncotarget.12657.

15. Noh KW, Park J, …, Kang MS. ERK2 phosphorylation of EBNA1 serine 383 residue is important for EBNA1-dependent transactivation. Oncotarget, 2016. https://doi.org/10.18632/oncotarget.8177.

16. Noh KW, Park J, Kang MS. Targeted disruption of EBNA1 in EBV-infected cells attenuated cell growth. BMB Rep, 2016. https://doi.org/10.5483/BMBRep.2016.49.4.260.

17. Lee EK, Kim SY, Noh KW, …, Kang MS. Small molecule inhibition of Epstein–Barr virus nuclear antigen-1 DNA binding activity interferes with replication and persistence of the viral genome. Antiviral Res, 2014. https://doi.org/10.1016/j.antiviral.2014.01.018.